[Form 3] CG Oncology, Inc. Common stock Initial Statement of Beneficial Ownership

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lapetina Bob

Role See Remarks

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 43,946 shares (Direct)

Footnotes (3)

1. F1. 1/4th of the shares subject to the option vested on May 15, 2025, the first anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments over the next 36 months, subject to the Reporting Person's continuous service to the Issuer through each vesting date
2. F2. 1/48th of the shares subject to the option vest monthly following October 4, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
3. F3. 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 08/06/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lapetina Bob

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/05/2025

3. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	05/15/2034	Common Stock	13,000	$28.01	D
Employee Stock Option (Right to Buy)	(2)	10/04/2034	Common Stock	9,360	$36.63	D
Employee Stock Option (Right to Buy)	(3)	04/15/2035	Common Stock	21,586	$20.11	D

Explanation of Responses:

1. 1/4th of the shares subject to the option vested on May 15, 2025, the first anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments over the next 36 months, subject to the Reporting Person's continuous service to the Issuer through each vesting date

2. 1/48th of the shares subject to the option vest monthly following October 4, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

3. 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Remarks:

Interim Principal Financial and Accounting Officer

	/s/ Joshua Patterson, Attorney-in-Fact for Robert Lapetina	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.